Annals of Hematology

, Volume 88, Issue 2, pp 97–110

Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

  • Angelika Böhme
  • Markus Ruhnke
  • Dieter Buchheidt
  • Oliver A. Cornely
  • Herrmann Einsele
  • Ruxandra Enzensberger
  • Holger Hebart
  • Werner Heinz
  • Christian Junghanss
  • Meinolf Karthaus
  • William Krüger
  • Utz Krug
  • Thomas Kubin
  • Olaf Penack
  • Dietmar Reichert
  • Stefan Reuter
  • Gerda Silling
  • Thomas Südhoff
  • Andrew J. Ullmann
  • Georg Maschmeyer
Review Article

Abstract

Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.

Keywords

Cancer Invasive fungal infections Antifungals 

References

  1. 1.
    Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91:142–150. doi:10.1016/0002-9343(91)90006-J PubMedGoogle Scholar
  2. 2.
    Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23:964–972PubMedGoogle Scholar
  3. 3.
    Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P (1997) Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 24:375–380PubMedGoogle Scholar
  4. 4.
    Baddour LM, Perfect JR, Ostrosky-Zeichner L (2005) Successful use of amphotericin B lipid complex in the treatment of cyptococcosis. Clin Infect Dis 40:S409–S413. doi:10.1086/429337 PubMedGoogle Scholar
  5. 5.
    Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H (1997) A comparison of amphotericin b alone and comnined with flucytosine in the treatment of crypococcal meningitis. N Engl J Med 301:126–131Google Scholar
  6. 6.
    Bernard A, Caillot D, Couaillier JF, Casasnovas O, Guy H, Favre JP (1997) Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 64:1441–1447. doi:10.1016/S0003-4975(97)00858-8 PubMedGoogle Scholar
  7. 7.
    Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S (2003) Treatment of fungal infections in hematology and oncology—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S133–S140. doi:10.1007/s00277-003-0767-1 PubMedGoogle Scholar
  8. 8.
    Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363:1764–1767. doi:10.1016/S0140-6736(04)16301-0 PubMedGoogle Scholar
  9. 9.
    Van Burik J-AH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis D (2006) Posaconazole is effectife as salvage therapy in zygomycosis: A retrospective Summary of 91 cases. Clin Infect Dis 42:e61–e65. doi:10.1086/500212 PubMedGoogle Scholar
  10. 10.
    Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous diseae, or AIDS. Clin Infect Dis 33:83–90. doi:10.1086/323020 Google Scholar
  11. 11.
    Caillot D, Casasnovas O, Bernard A, Couaillier J-F, Durand C, Cuisenier B (1997) Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15:139–147PubMedGoogle Scholar
  12. 12.
    Caillot D, Thiebaut A, Herbrecht R, de Botto S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L (2007) Liposomal amphotericin B in combination with caspofungin for invacive aspergillosis in patients with hematologic malignancies. Cancer 110:2740–2746. doi:10.1002/cncr.23109 PubMedGoogle Scholar
  13. 13.
    Chandra J, Zhou G, Ghannoum MA (2005) Fungal biofilms and antimycotics. Curr Drug Targets 6:887–894. doi:10.2174/138945005774912762 PubMedGoogle Scholar
  14. 14.
    Chandrasekar PH, Ito JI (2005) Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 40(Suppl 6):S392–S400. doi:10.1086/429333 PubMedGoogle Scholar
  15. 15.
    Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W (2003) Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol 82:93–97PubMedGoogle Scholar
  16. 16.
    Cordonnier C, Bresnik M, Ebrahimi R (2007) Liposomal amphotericin B (AmBisome R) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses 50:205–209. doi:10.1111/j.1439-0507.2007.01362.x PubMedGoogle Scholar
  17. 17.
    Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–1297. doi:10.1086/514341 PubMedGoogle Scholar
  18. 18.
    Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37:173–180. doi:10.1016/S0163-4453(98)80173-4 PubMedGoogle Scholar
  19. 19.
    Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53:337–349. doi:10.1016/j.jinf.2006.03.003 PubMedGoogle Scholar
  20. 20.
    Denning DW, Ribaud P, Milpied N, Herbrecht R, Thiel E, Haas A (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571. doi:10.1086/324620 PubMedGoogle Scholar
  21. 21.
    v. Eiff M, Essink M, Roos N, Hiddemann W, Buchner T, van de Loo J (1990) Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Blut 60:242–248Google Scholar
  22. 22.
    Einsele H, Bertz H, Beyer J, Kiehl MG, Runde V, Kolb HJ (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S175–S185. doi:10.1007/s00277-003-0772-4 PubMedGoogle Scholar
  23. 23.
    Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406–1412. doi:10.1086/515033 PubMedGoogle Scholar
  24. 24.
    Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31. doi:10.1086/504810 PubMedGoogle Scholar
  25. 25.
    Glasmacher A, Cornely OA, Orlopp K, Reuter S, Blaschke S, Eichel M (2006) Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother 57:127–134. doi:10.1093/jac/dki410 PubMedGoogle Scholar
  26. 26.
    Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1993) Treatment of Candida albicans fungaemia with fluconazole. J Infect 26:133–146. doi:10.1016/0163-4453(93)92761-K PubMedGoogle Scholar
  27. 27.
    Greenberg RN, Mullane K, van Burik J-AH, Raad I, Abzug MJ, Anstead G (2006) Posaconazole as salvage therapy for zygomycosis. Antimicroial Agents Chemother 50:126–133. doi:10.1128/AAC.50.1.126-133.2006 Google Scholar
  28. 28.
    Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ (2003) Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 17:159–191. doi:10.1016/S0891-5520(02)00068-5 PubMedGoogle Scholar
  29. 29.
    Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182:274–282. doi:10.1086/315643 PubMedGoogle Scholar
  30. 30.
    Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I (2008) The changing epidemiology of invasive candidiasis. Cancer 112:2493–2499. doi:10.1002/cncr.23466 PubMedGoogle Scholar
  31. 31.
    Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancies. Cancer 112:1282–1287. doi:10.1002/cncr.23311 PubMedGoogle Scholar
  32. 32.
    Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP (2004) Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101:1594–1600. doi:10.1002/cncr.20554 PubMedGoogle Scholar
  33. 33.
    Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:e120–e127. doi:10.1086/344468 PubMedGoogle Scholar
  34. 34.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415. doi:10.1056/NEJMoa020191 PubMedGoogle Scholar
  35. 35.
    Herbrecht R, Flückinger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C (2007) Treatment of invasive Candida and Aspergillus infections in adult haematological patients. EJC 5(Suppl 2):49–59Google Scholar
  36. 36.
    Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR (2001) Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 20:460–466PubMedGoogle Scholar
  37. 37.
    Heussel CP, Kauczor HU, Heussel G, Mildenberger P, Dueber C (1997) Aneurysms complicating inflammatory diseases in immunocompromised hosts: value of contrast-enhanced CT. Eur Radiol 7:316–319. doi:10.1007/s003300050157 PubMedGoogle Scholar
  38. 38.
    Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337:15–21. doi:10.1056/NEJM199707033370103 PubMedGoogle Scholar
  39. 39.
    Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 42:1414–1421. doi:10.1046/j.1537-2995.2002.00249.x PubMedGoogle Scholar
  40. 40.
    Ito JI, Chandrasekar PH, Hooshmand-Rad R (2005) Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant 36:873–877. doi:10.1038/sj.bmt.1705143 PubMedGoogle Scholar
  41. 41.
    Ito JI, Hooshmand-Rad R (2005) Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 40(Suppl 6):S384–S391. doi:10.1086/429330 PubMedGoogle Scholar
  42. 42.
    Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851–854. doi:10.1086/319366 PubMedGoogle Scholar
  43. 43.
    Kontoyiannis DP, Bodey GP (2002) Invasive aspergillosis in 2002: An update. Eur J Clin Microbiol Infect Dis 21:161–172. doi:10.1007/s10096-002-0699-z PubMedGoogle Scholar
  44. 44.
    Kontoyiannis DP, Lewis RE (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6:257–269. doi:10.1016/j.drup.2003.08.003 PubMedGoogle Scholar
  45. 45.
    Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP (2001) Cryptococcosis in patients with cancer. Clin Infect Dis 32:E145–E150. doi:10.1086/320524 PubMedGoogle Scholar
  46. 46.
    Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435–1442. doi:10.1016/S0140-6736(05)67490-9 PubMedGoogle Scholar
  47. 47.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519–1527. doi:10.1016/S0140-6736(07)60605-9 PubMedGoogle Scholar
  48. 48.
    Larkin JA, Montero JA (2003) Efficacy and safety of Amphotericin B Lipid Complex for zygomacosis. Infect Med 20:201–206Google Scholar
  49. 49.
    Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131:201–207. doi:10.1111/j.1365-2141.2005.05763.x PubMedGoogle Scholar
  50. 50.
    Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205–212. doi:10.1046/j.1365-2141.1998.00944.x PubMedGoogle Scholar
  51. 51.
    Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J (1997) Liposomal AmB (AmBisome) compared with AmB both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11:1463–1471. doi:10.1097/00002030-199712000-00010 PubMedGoogle Scholar
  52. 52.
    Leu HS, Huang CT (1995) Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 20:1152–1157PubMedGoogle Scholar
  53. 53.
    Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358–366. doi:10.1086/318483 PubMedGoogle Scholar
  54. 54.
    Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888–2897. doi:10.1002/cncr.22348 PubMedGoogle Scholar
  55. 55.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571. doi:10.1086/423381 PubMedGoogle Scholar
  56. 56.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2005) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797–802. doi:10.1086/423380 Google Scholar
  57. 57.
    Maschmeyer G, Haas A (2006) Defining clinical failure for salvage studies. Med Mycol 44:S315–S318. doi:10.1080/13693780600835690 Google Scholar
  58. 58.
    Maschmeyer G, Haas A, Cornely A (2007) Invasive aspergillosis. Epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567–1601. doi:10.2165/00003495-200767110-00004 PubMedGoogle Scholar
  59. 59.
    Matt P, Bernet F, Habicht J (2004) Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 126:1783–1788. doi:10.1378/chest.126.6.1783 PubMedGoogle Scholar
  60. 60.
    Mattiuzzi G, Giles FJ (2005) Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 131:287–300. doi:10.1111/j.1365-2141.2005.05749.x PubMedGoogle Scholar
  61. 61.
    Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ (2004) Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 33:543–548. doi:10.1038/sj.bmt.1704408 PubMedGoogle Scholar
  62. 62.
    Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754–760. doi:10.1111/j.1365-2141.1994.tb04825.x PubMedGoogle Scholar
  63. 63.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J (2002) Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029. doi:10.1056/NEJMoa021585 PubMedGoogle Scholar
  64. 64.
    Morrissey CO, Slavin MA, O’Reilly MA, Daffy JR, Seymour JF, Schwarer AP (2007) Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 50(Suppl 1):24–37. doi:10.1111/j.1439-0507.2007.01377.x PubMedGoogle Scholar
  65. 65.
    Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84:734–741. doi:10.1007/s00277-005-1055-z PubMedGoogle Scholar
  66. 66.
    Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155:2429–2435. doi:10.1001/archinte.155.22.2429 PubMedGoogle Scholar
  67. 67.
    Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marenco P (2007) Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 39:631–635. doi:10.1038/sj.bmt.1705655 PubMedGoogle Scholar
  68. 68.
    Offner F (1997) Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis 16:56–63. doi:10.1007/BF01575122 PubMedGoogle Scholar
  69. 69.
    Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24:654–661. doi:10.1007/s10096-005-0024-8 PubMedGoogle Scholar
  70. 70.
    Ostrosky-Zeichner L, Lashof A, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:651–655. doi:10.1007/s10096-003-1014-3 PubMedGoogle Scholar
  71. 71.
    Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425. doi:10.1086/376634 PubMedGoogle Scholar
  72. 72.
    Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075PubMedGoogle Scholar
  73. 73.
    Pagano L, Caira M, Falcucci P, Fianchi L (2005) Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther 3:775–777. doi:10.1586/14787210.3.5.775 PubMedGoogle Scholar
  74. 74.
    Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D (2002) Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 87:535–541PubMedGoogle Scholar
  75. 75.
    Pagano L, Ricci P, Offidani M, Fianchi L, Nosari A, Candoni A (2004) Mucormycosis in heamtolocic patients. Haematologica 89:207–214PubMedGoogle Scholar
  76. 76.
    Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A (2004) Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 189:2185–2191. doi:10.1086/420829 PubMedGoogle Scholar
  77. 77.
    Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189. doi:10.1086/380796 PubMedGoogle Scholar
  78. 78.
    Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883–893. doi:10.1086/520980 PubMedGoogle Scholar
  79. 79.
    Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211. doi:10.1086/524669 PubMedGoogle Scholar
  80. 80.
    Penack O, Beinert T, Buchheidt D, Einsele H, Hebart H, Kiehl MG (2006) Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 85:424–433. doi:10.1007/s00277-006-0096-2 PubMedGoogle Scholar
  81. 81.
    Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti L (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106:4397–4406. doi:10.1182/blood-2005-05-1775 PubMedGoogle Scholar
  82. 82.
    Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 16:337–345. doi:10.1007/BF01726360 PubMedGoogle Scholar
  83. 83.
    Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S (2005) Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56:745–755. doi:10.1093/jac/dki288 PubMedGoogle Scholar
  84. 84.
    Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM (1992) A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical trials Group and Mycoses Study Group. N Engl J Med 326:793–798PubMedGoogle Scholar
  85. 85.
    Price TH (2007) Granulocyte transfusion: current status. Semin Hematol 44:15–23. doi:10.1053/j.seminhematol.2006.09.015 PubMedGoogle Scholar
  86. 86.
    Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42:1726–1734. doi:10.1086/504328 PubMedGoogle Scholar
  87. 87.
    Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M (2004) Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38:1119–1127. doi:10.1086/382874 PubMedGoogle Scholar
  88. 88.
    Raad I, Hanna HA, Boktour M, Jiang Y, Afif C, Kontoyiannis DP, Hachem RY (2008) Novel antifungal agents as salvage therapy for invasive aspergilllosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496–503. doi:10.1038/sj.leu.2405065 PubMedGoogle Scholar
  89. 89.
    Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472–2482. doi:10.1056/NEJMoa066906 PubMedGoogle Scholar
  90. 90.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325–1330. doi:10.1056/NEJM199411173312001 PubMedGoogle Scholar
  91. 91.
    Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36:1221–1228. doi:10.1086/374850 PubMedGoogle Scholar
  92. 92.
    Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28(suppl B):73–82PubMedGoogle Scholar
  93. 93.
    Roden MR, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL (2005) Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 41:634–653. doi:10.1086/432579 PubMedGoogle Scholar
  94. 94.
    Ruhnke M, Kofla G, Otto K, Schwartz S (2007) CNS aspergillosis. CNS Drugs 21:659–676. doi:10.2165/00023210-200721080-00004 PubMedGoogle Scholar
  95. 95.
    Saag MS, Graybill RJ, Larsen RA (2000) Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 30:710–717. doi:10.1086/313757 PubMedGoogle Scholar
  96. 96.
    Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B (2004) Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 101:2859–2865. doi:10.1002/cncr.20710 PubMedGoogle Scholar
  97. 97.
    Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II (2005) The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103:731–739. doi:10.1002/cncr.20883 PubMedGoogle Scholar
  98. 98.
    Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P (1999) Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 106:697–701. doi:10.1046/j.1365-2141.1999.01592.x PubMedGoogle Scholar
  99. 99.
    Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641–2645. doi:10.1182/blood-2005-02-0733 PubMedGoogle Scholar
  100. 100.
    Segal BH, Kwon-Chung J, Walsh TJ, Klein BS, Battiwalla M, Almyroudis NG (2006) Immunotherapy for fungal infections. Clin Infect Dis 42:507–515. doi:10.1086/499811 PubMedGoogle Scholar
  101. 101.
    Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Böhme A et al. (2008) Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant (in press)Google Scholar
  102. 102.
    DeShazo RD, Chapin K, Swain RE (1997) Fungal sinusitis. N Engl J Med 337:254–259. doi:10.1056/NEJM199707243370407 PubMedGoogle Scholar
  103. 103.
    Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451 PubMedGoogle Scholar
  104. 104.
    Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW (2000) Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30:19–24. doi:10.1086/313580 PubMedGoogle Scholar
  105. 105.
    Spellberg BJ, Filler SG, Edwards JE (2006) Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42:244–251. doi:10.1086/499057 PubMedGoogle Scholar
  106. 106.
    Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30:696–709. doi:10.1086/313756 Google Scholar
  107. 107.
    Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE (1994) Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 57:1044–1050PubMedGoogle Scholar
  108. 108.
    Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43:e29–e38. doi:10.1086/505969 PubMedGoogle Scholar
  109. 109.
    Viollier AF, Peterson DE, De Jongh CA, Newman KA, Gray WC, Sutherland JC (1986) Aspergillus sinusitis in cancer patients. Cancer 58:366–371. doi:10.1002/1097-0142(19860715)58:2<366::AID-CNCR2820580228>3.0.CO;2-V PubMedGoogle Scholar
  110. 110.
    Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071–1079. doi:10.1086/514731 PubMedGoogle Scholar
  111. 111.
    Walsh TJ (1998) Primary cutaneous aspergillosis —an emerging infection among immunocompromised patients. Clin Infect Dis 27:453–457. doi:10.1086/514718 PubMedGoogle Scholar
  112. 112.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360. doi:10.1086/525258 PubMedGoogle Scholar
  113. 113.
    Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12. doi:10.1086/508774 PubMedGoogle Scholar
  114. 114.
    Wolf HH, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I et al. (2008) Central venous catheter-related infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 87:863–876PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Angelika Böhme
    • 1
  • Markus Ruhnke
    • 2
  • Dieter Buchheidt
    • 3
  • Oliver A. Cornely
    • 4
  • Herrmann Einsele
    • 5
  • Ruxandra Enzensberger
    • 6
  • Holger Hebart
    • 7
  • Werner Heinz
    • 8
  • Christian Junghanss
    • 9
  • Meinolf Karthaus
    • 10
  • William Krüger
    • 11
  • Utz Krug
    • 12
  • Thomas Kubin
    • 13
  • Olaf Penack
    • 14
  • Dietmar Reichert
    • 15
  • Stefan Reuter
    • 16
  • Gerda Silling
    • 17
  • Thomas Südhoff
    • 18
  • Andrew J. Ullmann
    • 19
  • Georg Maschmeyer
    • 20
  1. 1.ONKOLOGIKUM, Frankfurt am MuseumsuferFrankfurtGermany
  2. 2.Abt. Onkologie und Hämatologie, Med. Klinik u. Poliklinik IICharité Universitätsmedizin, Campus Charité MitteBerlinGermany
  3. 3.III. Medizinische KlinikUniversitätsklinikum Mannheim GmbHMannheimGermany
  4. 4.Klinik I für Innere Medizin und Zentrum für Klinische Studien (ZKS) 01KN0706Klinikum der Universität KölnKölnGermany
  5. 5.Medizinische Klinik und Poliklinik IIUniversitätsklinikum WürzburgWürzburgGermany
  6. 6.Institut für Medizinische Mikrobiologie und KrankenhaushygieneJ.W. Goethe-UniversitätFrankfurtGermany
  7. 7.Zentrum für Innere MedizinKlinikum Schwäbisch Gmünd/StauferklinikMutlangenGermany
  8. 8.Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik IIUniversitätsklinikum WürzburgWürzburgGermany
  9. 9.Abt. Hämatologie und Onkologie. Klinik und Poliklinik für Innere MedizinUniversität RostockRostockGermany
  10. 10.Abt. Hämatologie/OnkologieSt. Klinikum München-NeuperlachMünchenGermany
  11. 11.Medizinische Klinik CErnst-Moritz-Arndt-UniversitätGreifswaldGermany
  12. 12.Medizinische Klinik AMedizinische UniversitätsklinikMünsterGermany
  13. 13.Hämatologie/OnkologieKlinikum TraunsteinTraunsteinGermany
  14. 14.Klinik für Hämatologie und OnkologieCharité, Campus Benjamin FranklinBerlinGermany
  15. 15.Hämatologisch-Onkologische Gemeinschaftspraxis Dr. Reichert/Dr. JanssenWesterstedeGermany
  16. 16.Klinik für Gastroenterologie, Hepatologie und InfektiologieUniversitätsklinikum DüsseldorfDüsseldorfGermany
  17. 17.Innere Medizin AMed. UniversitätsklinikMünsterGermany
  18. 18.II. Medizinische KlinikKlinikum PassauPassauGermany
  19. 19.3. Medizinische AbteilungJohannes Gutenberg-UniversitätMainzGermany
  20. 20.Medizinische Klinik, Hämatologie und OnkologieKlinikum Ernst von BergmannPotsdamGermany

Personalised recommendations